FORCE: FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Sponsor

Kaiser Permanente (Other)

Overall Status

Completed

CT.gov ID

NCT03291951

Collaborator

Dana-Farber Cancer Institute (Other), Penn State University (Other)

183

Enrollment

Locations

Arms

48.9

Actual Duration (Months)

Patients Per Site

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

FORCE is a randomized home-based resistance training/strength training (RT) intervention study for Stage II and III colon cancer patients undergoing chemotherapy.

Participants will be 180 newly diagnosed Stage II and III colon cancer patients from Kaiser Permanente of Northern California (KPNC), the Penn State Cancer Institute (PSCI), and the Dana Farber Cancer Institute (DFCI). The intervention will begin within the first weeks of adjuvant chemotherapy and continue exercise through the completion of post-operative chemotherapy. Specifically, the investigators will examine between group differences for RT versus waitlist control for chemotherapy outcomes including dose delays, dose reductions, early stoppage and Grade 3 and 4 toxicities. The investigators will also study changes in muscle mass (MM) and changes in specific inflammatory markers (e.g. CRP, IL-6 and TNF-RII) as potential markers of change in response to RT. To determine effects of change of MM on chemotherapy-specific drug clearance, the investigators will examine the impact body composition changes on the pharmacokinetics (PK) of 5-FU and oxaliplatin, two of the most commonly used drugs for colon cancer.

Condition or Disease	Intervention/Treatment	Phase
Resistance Training Colon Cancer Chemotherapy Effect	Behavioral: Resistance training	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

183 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

This randomized controlled trial of resistance training intervention in colon cancer patients receiving chemotherapy consists of two arms: an in-person and telephone-based intervention to promote home-based resistance training, and a wait-list, control group.This randomized controlled trial of resistance training intervention in colon cancer patients receiving chemotherapy consists of two arms: an in-person and telephone-based intervention to promote home-based resistance training, and a wait-list, control group.

Masking:

None (Open Label)

Primary Purpose:

Supportive Care

Official Title:

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Actual Study Start Date :

Feb 23, 2018

Actual Primary Completion Date :

Mar 21, 2022

Actual Study Completion Date :

Mar 21, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Resistance training group Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.	Behavioral: Resistance training The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
No Intervention: Usual care group Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.

Arm

Intervention/Treatment

Experimental: Resistance training group

Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.

Behavioral: Resistance training

The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.

No Intervention: Usual care group

Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.

Outcome Measures

Primary Outcome Measures

Relative dose intensity (RDI) [3-6 months]
Chemotherapy completion rates will be assessed as relative dose intensity for each agent and then average relative dose intensity (ARDI), which considers all chemotherapy agents in a regimen. We will examine differences in RDI for each chemotherapy agent and the ARDI across all agents between the RT group and the UC group.
Number of moderate and severe chemotherapy-associated toxicities [3-6 months]
Moderate and severe chemotherapy-associated toxicities will be assessed via a NCI PRO-CTCAE questionnaire, which is a patient-reported outcome measure developed to evaluate symptomatic toxicity in patients on cancer clinical trials.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Men and women ≥18 years
Newly diagnosed with histologically confirmed stage II-Ill colon cancer
Completed curative-intent surgical resection
Currently prescribed one of the following adjuvant chemotherapy regimens: (IV 5-fluorouracil [5-FU] / leucovorin [LV], capecitabine, FOLFOX [5-FU, LV, oxaliplatin], CAPOX [capecitabine and oxaliplatin]
Patients must have started chemotherapy or plan to start with receipt of the first exercise visit by 3rd infusion visit. Patients enrolled at the Dana-Farber Cancer Institute and who are receiving FOLFOX chemotherapy are eligible to enroll in the pharmacokinetics sub-study.
No planned major surgery anticipated in the intervention period
Sufficient time to heal from any major surgery to start of intervention, including colostomy reversal (port-a-cath removal excluded)
Approval by either oncologist or surgeon to participate in trial
Readiness as determined by the Physical Activity Readiness Questionnaire
Ability to understand and the willingness to sign a written informed consent document in English
Willingness to be randomized

Exclusion Criteria:

Concurrent actively treated other cancer (except non-melanoma skin cancer, in situ cervical cancer or localized prostate cancer treated with surveillance only)
Patients with untreated hypertension (>180 mm Hg systolic or >100 mm Hg diastolic) appearing in the patient's medical record in the two weeks prior to screening
Presence of metastatic disease
Current strength training >2x week for the past 3 or more months
Patients enrolled in other clinical trials of weight loss, physical activity or dietary interventions are ineligible.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Kaiser Permanente Division of Research	Oakland	California	United States	94612
2	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02215
3	Penn State Cancer Institute	Hershey	Pennsylvania	United States	17033

Sponsors and Collaborators

Kaiser Permanente
Dana-Farber Cancer Institute
Penn State University

Investigators

Principal Investigator: Bette J Caan, DrPH, Kaiser Permanente
Principal Investigator: Kathryn H Schmitz, PhD, MPH, Penn State Cancer Institute
Principal Investigator: Jeffrey Meyerhardt, MD, MPH, Dana-Farber Cancer Institute

Study Documents (Full-Text)

More Information

Publications

None provided.

Responsible Party:

Kaiser Permanente

ClinicalTrials.gov Identifier:

NCT03291951

Other Study ID Numbers:

CN-17-2877

First Posted:

Sep 25, 2017

Last Update Posted:

Jul 28, 2022

Last Verified:

Jul 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Colonic Neoplasms

Study Results

No Results Posted as of Jul 28, 2022